Literature DB >> 12051865

Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy.

Terence J Colgan1, Scott L Boerner, Joan Murphy, David E C Cole, Steven Narod, Barry Rosen.   

Abstract

OBJECTIVE: Prophylactic oophorectomy (PO) is an accepted treatment strategy for women who are at high risk for the development of ovarian carcinoma, particularly women who are BRCA mutation-positive. This study sought to assess the utility of peritoneal lavage cytology at the time of PO in detecting occult malignancy in this group of patients.
METHODS: Thirty-five high-risk women, who were not suspected of having any malignancy or ovarian mass, underwent peritoneal lavage at the time of PO. Thirty-one of the thirty-five women had undergone BRCA mutation analysis (BRCA1+, 18; BRCA2+, 10; BRCA-, 3). Intensive histopathologic examination was used in all 35 cases to identify occult carcinoma. Lavage specimens were reviewed for the presence of malignant cells and endosalpingiosis. The cytologic review was conducted without knowledge of either the histopathologic or BRCA results.
RESULTS: In 32 of the 35 lavage specimens no malignancy was detected. In the remaining three cases malignant cells were detected; in two of these cases histopathologic examination confirmed an ovarian/tubal occult carcinoma. Two of these women were BRCA1 mutation positive. Endosalpingiosis was detected in the peritoneal lavage specimens of 7 of the 32 cases showing no evidence of malignancy. All of these 7 women were BRCA mutation positive or unknown.
CONCLUSION: Peritoneal lavage cytology can detect occult carcinoma at the time of PO and should be performed at PO. The significance of occult carcinoma detected by either histopathologic or cytopathologic examination is uncertain. Whether the prevalence of endosalpingiosis detectable by lavage cytology is increased in BRCA mutation-positive patients requires further study.

Entities:  

Mesh:

Year:  2002        PMID: 12051865     DOI: 10.1006/gyno.2002.6638

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

1.  Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

Authors:  G Landon; J Stewart; M Deavers; K Lu; N Sneige
Journal:  Gynecol Oncol       Date:  2012-03-13       Impact factor: 5.482

2.  Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.

Authors:  C B Powell; E M Swisher; I Cass; J McLennan; B Norquist; R L Garcia; J Lester; B Y Karlan; L Chen
Journal:  Gynecol Oncol       Date:  2013-02-04       Impact factor: 5.482

Review 3.  Genetic risk and gynecologic cancers.

Authors:  Laura L Holman; Karen H Lu
Journal:  Hematol Oncol Clin North Am       Date:  2012-02       Impact factor: 3.722

Review 4.  Intra-operative peritoneal lavage for colorectal cancer.

Authors:  Guillaume Passot; Kayvan Mohkam; Eddy Cotte; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

5.  Detection methods and clinical significance of free peritoneal tumor cells found during colorectal cancer surgery.

Authors:  Simone Sibio; Cristina Fiorani; Carmine Stolfi; Andrea Divizia; Roberto Pezzuto; Fabrizio Montagnese; Giulia Bagaglini; Paolo Sammartino; Giuseppe Sigismondo Sica
Journal:  World J Gastrointest Surg       Date:  2015-09-27

6.  Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen Abushahin; Cynthia Laughren; Wenxin Zheng; Setsuko K Chambers
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

Review 7.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 8.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

Review 9.  Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer.

Authors:  Elizabeth Swisher
Journal:  Curr Treat Options Oncol       Date:  2003-04

10.  Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.

Authors:  B E Kiely; M L Friedlander; R L Milne; L Stanhope; P Russell; M A Jenkins; P Weideman; S A McLachlan; P Grant; J L Hopper; K A Phillips
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.